Key Developments: Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

31 Mar 2015
Change (% chg)

$-0.22 (-0.35%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Teva Pharmaceutical Industries Ltd's Teva Canada Ltd announces launch of bortezomib for injection
Monday, 30 Mar 2015 02:04pm EDT 

Teva Pharmaceutical Industries Ltd:Teva Canada Ltd, a subsidiary of Teva Pharmaceutical Industries Ltd, says that Health Canada has approved its application for generic version of bortezomib for injection for following indications.As part of combination therapy for treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation.For treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for stem cell transplantation.For treatment of patients with mantle cell lymphoma who have relapsed or were refractory to at least one prior therapy.  Full Article

Teva Pharmaceutical Industries Ltd announces acquisition of Auspex Pharmaceuticals
Monday, 30 Mar 2015 07:00am EDT 

Teva Pharmaceutical Industries Ltd:Says the company and Auspex Pharmaceuticals, Inc have entered into a definitive merger agreement under which Teva will commence a tender offer for all of the outstanding shares of Auspex at $101.00 per share in cashn.Representing total consideration of about $3.2 bln in enterprise value and about $3.5 b in equity value.Under the terms of the merger agreement, an affiliate of Teva will promptly commence a tender offer to acquire all of the outstanding shares of Auspex's common stock for $101 per share in cash.Following the completion of the tender offer, Teva will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price as to be paid to stockholders tendering their shares in the tender offer.Goldman, Sachs & Co. is acting as the exclusive financial advisor to Teva and Goodwin Procter LLP is serving as legal counsel to Teva.J.P. Morgan Securities LLC is acting as the exclusive financial advisor to Auspex and Cooley LLP is serving as legal counsel to Auspex.  Full Article

Teva Pharmaceutical Industries Ltd prices 2 billion euors of senior notes
Tuesday, 24 Mar 2015 04:41pm EDT 

Teva Pharmaceutical Industries Ltd:Prices 2 billion euros debt offering, comprised of two tranches.Says 1.3 billion euros principal amount of 1.25 pct senior notes due March 2023 and 700 million euros principal amount of 1.875 pct senior notes due March 2027.Says notes will be issued by Teva Pharmaceutical Finance Netherlands II B.V., a finance subsidiary of Teva, and will be guaranteed by Teva.Says 2023 notes and 2027 notes are being sold at a price of 990.59 euros and 995.01 euros per 1,000 euros principal amount, respectively.Says it intends to use proceeds of offering for general corporate purposes.  Full Article

Teva Pharmaceutical Industries Ltd and Ignyta announces acquisition by Ignyta of Four Oncology R&D Assets from Teva
Tuesday, 17 Mar 2015 04:00pm EDT 

Teva Pharmaceutical Industries Ltd and Ignyta Inc:Says acquisition by Ignyta of the worldwide rights and assets relating to four targeted oncology development programs in exchange for 1.5 million shares (6 pct) of Ignyta's common stock.Concurrently, Ignyta has entered into stock purchase agreements with Teva, and selected additional healthcare investors, whereby Teva will purchase a further 1.5 million shares of common Ignyta stock at a price of $10 per share in a registered direct offering.The other investors will purchase an additional 2.7 million shares at $10 per share, valuing the total offering at about $41.6 million.  Full Article

Teva Pharmaceutical Industries announces sale of Sellersville, PA Facility
Monday, 2 Mar 2015 08:22am EST 

Teva Pharmaceutical Industries Ltd:Says it has signed an agreement to sell its Sellersville, pennsylvania facility to G&W Laboratories, Inc.Sale supports its plans to streamline operations by reducing excess manufacturing capacity and is part of the Company's previously announced cost reduction program.Under the terms of the agreement, G&W will manufacture and supply products to Teva from the site until production of these products is transferred to other sites in Teva's network.Transaction includes the sale to G&W of about 25 products from the Teva portfolio, which will be manufactured and sold by G&W in the U.S. under the G&W label.  Full Article

Teva Pharmaceutical Industries announces FDA acceptance for review of NDA for investigational twice-daily hydrocodone bitartrate extended-release tablets with proprietary abuse deterrence technology
Wednesday, 25 Feb 2015 08:00am EST 

Teva Pharmaceutical Industries Ltd:Says the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the company's hydrocodone bitartrate extended-release (ER) tablets formulated with Teva's proprietary abuse deterrence technology (CEP-33237).NDA filing is supported by a clinical program that evaluated the safety and efficacy of CEP-33237, as well as the abuse potential of CEP-33237 via the oral and intranasal routes of abuse in Human Abuse Liability (HAL) studies.  Full Article

Teva Pharmaceutical Industries announces positive results for TEV-48125 in phase IIb chronic migraine study meeting primary and secondary endpoints
Tuesday, 24 Feb 2015 09:00am EST 

Teva Pharmaceutical Industries Ltd:Says positive results from a Phase IIb study evaluating the efficacy, safety and tolerability of two doses of subcutaneous TEV-48125, an investigational anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of chronic migraine.Study compared two active arms of different doses of TEV-48125, administered as a subcutaneous injection, once a month for three months, against placebo.Results demonstrated that both tested doses of TEV-48125 achieved the primary and secondary efficacy endpoints of the study at one and three months.  Full Article

The Lancet Respiratory Medicine and AAAAI publish positive data from phase III trials of Teva Pharmaceutical's Reslizumab
Monday, 23 Feb 2015 03:00pm EST 

Teva Pharmaceutical Industries Ltd:Says the Lancet Respiratory Medicine has published data from two replicate 52-week Phase III global studies on the company's investigational anti-interleukin-5 (IL-5) monoclonal antibody, reslizumab.Data showed that treatment with reslizumab significantly reduced the annual rate of clinical asthma exacerbations, significantly improved lung function, and provided sustained improvement in multiple secondary measures of asthma control in patients with asthma and elevated blood eosinophils.  Full Article

Teva Pharmaceutical Industries Ltd reaffirms FY 2015 guidance; declares Q4 2014 cash dividend
Thursday, 5 Feb 2015 07:00am EST 

Teva Pharmaceutical Industries Ltd:Reaffirms FY 2015 guidance as reported earlier.Sees FY 2015 net revenue to be in the range of $19.0-$19.4 bln.Sees FY 2015 operating income in the range of $5.7-$5.9 bln.Sees FY 2015 EPS in the range of $5.00-$5.30.FY 2015 revenue of $19.4 bln, EBIT of $5.5 bln and EPS of $5.14 - Thomson Reuters I/B/E/S.Declares a cash dividend for the Q4 2014 of NIS 1.33 per share (about 34 cents according to the rate of exchange on Feb.3, 2015).Says the record date will be Feb.19 and the payment date will be March 3.Says commencing in April 2015, dividends will be declared and paid in U.S. dollars.  Full Article

Teva Pharmaceutical Industries Ltd receives FDA approval for first Generic Nexium delayed-release capsules in the United States
Monday, 26 Jan 2015 03:23pm EST 

Teva Pharmaceutical Industries Ltd:Announces the Food and Drug Administration (FDA) approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States.  Full Article


Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion

TEL AVIV - Israel's Teva Pharmaceutical Industries said it would buy U.S. neurology drug company Auspex Pharmaceuticals Inc for an equity value of $3.5 billion to boost its portfolio of treatments for the central nervous system.

Search Stocks